Clinical Trials in New York

Showing 6821-6840 of 22,668 trials

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

NCT05862324

TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.

Metastatic Solid Tumor

Triumvira Immunologics, Inc.113 participantsStarted Aug 2023

Los Angeles, California, United States • San Diego, California, United States • Miami, Florida, United States +6 more locations

COMPLETEDPhase 1< 1 mile

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

NCT04372433

To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)

AML With Monocytic DifferentiationCMML

Immune-Onc Therapeutics67 participantsStarted Sep 2020

Davis, California, United States • Duarte, California, United States • Irvine, California, United States +11 more locations

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Find Trials by Condition in New York

Investigation of the Pharmacokinetic Profile of CBD

Myeloma-Developing Regimens Using Genomics (MyDRUG)

Video Consultation to Reduce Drug Interactions Among Patients Initiating Oral Anti-Cancer Drugs

Reducing Self-Stigma Among Individuals with History of Childhood Maltreatment

A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer

Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF

Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

COVID-19 Vaccine Response in Sickle Cell Disease

Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Evaluation of the Phased Radio Frequency Ablation System

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

Alcoholic Hepatitis Network Observational Study

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

ArcticLine Feasibility Study